Tirzepatide Outperforms Semaglutide on Weight and Metabolic Health in New Comparison

The battle between the two most powerful weight-loss drugs on the market has just gained a new layer of evidence. A team of researchers led by Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona has published an indirect treatment comparison in the International Journal of Obesity suggesting that tirzepatide, the dual-action injectable marketed for obesity, beats semaglutide, a pure GLP-1 receptor agonist, on nearly every measure that matters in obesity medicine. The analysis, funded by Eli Lilly, tirzepatide’s manufacturer, pooled data from the two pivotal phase 3 trials that established each drug’s credentials and asked a deceptively simple question: if patients had been enrolled in the same trial, which drug would have delivered greater benefit?

Because no large head-to-head trial had previously compared every licensed dose of the two drugs across a full panel of outcomes, the researchers turned to an established statistical technique known as the Bucher indirect treatment comparison. The method anchors two randomized controlled trials that share a common comparator, in this case placebo, and mathematically derives the relative effect of the two active treatments. The team drew on SURMOUNT-1, the 72-week trial that tested tirzepatide at 5, 10 and 15 milligrams per week, and STEP 1, the 68-week trial that tested semaglutide at 2.4 milligrams per week. Both trials enrolled adults with obesity, defined as a body mass index of 30 or higher, or overweight with at least one weight-related complication such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, and both excluded people with type 2 diabetes.

The statistical machinery behind the comparison was more elaborate than a simple subtraction. Before running any numbers, the researchers assessed whether the two trials were similar enough to be compared at all, examining trial design, baseline patient characteristics, placebo responses and outcome definitions. They identified sex and ethnicity as potential treatment effect modifiers, since SURMOUNT-1 enrolled 67.5 percent women and 47.8 percent Hispanic participants while STEP 1 enrolled 74.1 percent women and only 12.0 percent Hispanic participants. To test whether these imbalances distorted the results, they repeated the analysis using matching-adjusted indirect comparisons, a technique that reweights individual patient data from one trial so that its population matches the aggregate characteristics of the other. Reassuringly, the adjusted and unadjusted analyses told broadly the same story.

The headline finding concerns weight itself. Tirzepatide at 10 and 15 milligrams produced statistically significantly greater weight reductions than semaglutide 2.4 milligrams, with mean differences of 5.10 and 6.50 kilograms respectively in favor of tirzepatide. Body mass index fell correspondingly further, by 1.87 and 2.37 kilograms per square meter. Patients on the higher tirzepatide doses were also significantly more likely to cross clinically meaningful thresholds, achieving weight losses of at least 10, 15 and 20 percent of their starting body weight more often than those on semaglutide. The lowest tirzepatide dose, 5 milligrams, showed only non-significant trends in the same direction, effectively performing at a level similar to semaglutide. These numbers align closely with the raw trial results, where tirzepatide 10 and 15 milligrams produced losses of 22.2 and 23.6 kilograms against semaglutide’s 17.4 kilograms.

What sets this analysis apart from earlier comparisons is its reach beyond the bathroom scale. Tirzepatide 10 and 15 milligrams were associated with significantly greater reductions in waist circumference, roughly 5.25 and 5.75 centimeters, a marker of visceral adiposity closely tied to cardiovascular risk. Glycemic control also favored the dual agonist, with small but statistically significant additional reductions in HbA1c and fasting plasma glucose even though all participants had normal glucose metabolism at baseline. Blood pressure told a similar story: every tirzepatide dose produced significantly greater drops in diastolic pressure than semaglutide, ranging from 1.30 to 2.40 millimeters of mercury, while systolic improvements trended in the same direction without reaching significance.

The lipid panel added further nuance. All three tirzepatide doses were associated with significantly greater increases in HDL cholesterol, the so-called good cholesterol, ranging from 3.80 to 5.40 percent relative to semaglutide. The highest dose also produced a significantly greater reduction in triglycerides, and in the adjusted analyses it significantly outperformed semaglutide on total cholesterol as well. Taken together, the authors argue, these improvements across waist circumference, glycemia, HDL, triglycerides and blood pressure suggest tirzepatide could meaningfully shift the constellation of risk factors that define metabolic syndrome, the cluster of abnormalities that precedes type 2 diabetes and cardiovascular disease in millions of people worldwide.

Perhaps the most novel contribution involves body composition, an outcome no previous tirzepatide-versus-semaglutide comparison has examined. In the subgroup of participants who underwent dual-energy X-ray absorptiometry scanning, tirzepatide 15 milligrams was associated with a significantly greater reduction in the percentage of body fat mass, 3.50 percent beyond semaglutide, and a significantly greater increase in the percentage of lean mass, 3.40 percent. All participants on both drugs lost some lean tissue along with fat, an expected consequence of substantial weight loss, but the proportion of the body composed of lean mass shifted more favorably with tirzepatide, likely because absolute fat losses were larger. Visceral fat reductions were similar between the drugs.

Safety, the perennial concern with these gut-hormone mimetics, showed no decisive winner. Gastrointestinal adverse events, nausea and discontinuations due to side effects all trended slightly higher with tirzepatide 10 and 15 milligrams, but none of these differences reached statistical significance. All-cause discontinuation actually favored tirzepatide, with significantly lower odds in several of the adjusted analyses. The authors caution that the placebo arms of the two trials showed different rates of gastrointestinal events, which could subtly bias safety conclusions, and they note that the open-label design of the recent head-to-head SURMOUNT-5 trial may introduce more bias than the double-blind trials used here.

The findings arrive with important caveats. The evidence base rests on just two trials, comparisons were only possible at outcomes both trials reported, and the body composition analyses relied on smaller DEXA subgroups that could not be population-adjusted. The timepoints differed by four weeks, though outcomes had plateaued by then, and STEP 1 included European patients while SURMOUNT-1 did not. The study is also industry-sponsored, with most authors employed by Eli Lilly. Still, the results mirror the direct head-to-head SURMOUNT-5 trial, which found tirzepatide superior on weight and waist circumference, and they extend that picture to individual licensed doses and a far broader set of metabolic outcomes. For clinicians and patients weighing the two injectables, the emerging consensus is becoming hard to ignore: at 10 or 15 milligrams, tirzepatide appears to offer more weight loss, better body composition and broader cardiometabolic benefit than semaglutide 2.4 milligrams, with a safety profile that is, on the evidence so far, essentially equivalent.

Subject of Research: Indirect comparison of tirzepatide versus semaglutide efficacy and safety for obesity treatment in adults without type 2 diabetes

Article Title: Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Article References: Ciudin, A., Johansson, E., Zimner-Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J.-F. (2026). Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02229-6

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02229-6

Keywords: tirzepatide, semaglutide, obesity, weight loss, GLP-1 receptor agonist, GIP, indirect treatment comparison, SURMOUNT-1, STEP 1, cardiometabolic risk factors, body composition, International Journal of Obesity